造血干细胞移植后肝静脉闭塞病的临床观察  

Clinical observsion of hepatic veno-occlusive disease after hematopoietic stem cell transplantation

作　　者：夏凌辉[1] 方峻[1] 游泳[1] 刘芳[1] 谢薇[1] 胡俊斌[1] 宋善俊[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院血液病研究所,武汉430022

出　　处：《临床内科杂志》2007年第2期98-100,共3页Journal of Clinical Internal Medicine

摘　　要：目的探讨造血干细胞移植(HSCT)后肝静脉闭塞病(HVOD)的临床特征、相关危险因素。方法用回顾性分析方法对145例HSCT患者移植后HVOD的发病情况进行临床分析。结果145例患者中,发生HVOD8例,发生率为5.5%。对HVOD的相关危险因素分析发现,HSCT患者移植前乙型肝炎表面抗原(HbsAg)阳性或HBV-DNA阳性患者HVOD发生率显著增高,是HVOD发生的高危因素(P(0.01);PGE1脂质微球(Lipo-PGE1)预防HVOD的效果显著优于PGE1组(P(0.05),原因可能与本组病例PGE1预防剂量相对不足有关。结论HVOD是HSCT常见并发症之一,移植前患者感染乙型肝炎病毒是其发生的高危因素;Lipo-PGE1对HVOD具有较好的预防效果。Objective To investigate the clinical characteristics,associated risk factors of hepatic veno-occlusive disease（HVOD） after hematopoietic stem cell transplantation （HSCT）. Methods 145 patients with hematological disorders underwent HSCT. The clinical data of HVOD were analyzed by retrospective method. Results HVOD was diagnosed in 8 patients from 145 cases and the incidence rate was 5.5%. The associated risk factors of HVOD were analyzed. We found that antigen or DNA of hepatitis B virus positive was the important risk factor for the development of HVOD （P 〈0.01 ） ;HVOD prevention regime with lipo-PGE, was better than that with PGE1 （ P 〈 0.05）. The result might be correlated with insufficient doseage of PGE1. Conclusion HVOD is a common complication after HSCT. The high risk factor is the infection of hepatitis B virus. Lipo-PGE1 is an effective drug for the prevention of HVOD after HSCT.

关 键 词：造血干细胞移植 肝静脉闭塞病 乙型肝炎病毒 

分 类 号：R457.1[医药卫生—治疗学]